Big Pharma M&A Activity Surges as Companies Target Undervalued Biotechs Amid Market Recovery
Pharmaceutical M&A activity is experiencing a significant rebound with major deals including Novartis's $1.7 billion acquisition of Regulus Therapeutics and Merck KGaA's $3.9 billion purchase of SpringWorks Therapeutics.
Merigolix Shows Promise in Multiple Indications as TiumBio's Oral GnRH Antagonist Advances in Clinical Trials
TiumBio's oral GnRH antagonist merigolix successfully met primary endpoints in Phase 2 trials for uterine fibroids, demonstrating significant reduction in heavy menstrual bleeding across all dosage groups compared to placebo.
OliX and Eli Lilly Forge $630M Deal for Novel RNAi Therapy Targeting MASH and Obesity
OliX Pharmaceuticals has secured a landmark $630 million licensing agreement with Eli Lilly for OLX75016, an RNAi-based therapeutic targeting MASH and obesity.
Merck Forges Ahead with Bispecific Antibody and Oral GLP-1 Agonist, Updates Immuno-oncology Programs
Merck has finalized an exclusive global license agreement with LaNova Medicines Ltd. for LM-299, a novel investigational PD-1/VEGF bispecific antibody, to develop, manufacture, and commercialize the compound.
Merck Enters Obesity Market with $112M Deal for Hansoh's Oral GLP-1 Drug
Merck & Co. has secured global rights outside China to Hansoh Pharma's preclinical oral GLP-1 receptor agonist for obesity treatment through a $112 million upfront payment.
GSK's GSK'227 Receives FDA Breakthrough Therapy Designation for Relapsed Osteosarcoma
The FDA granted Breakthrough Therapy Designation to GSK'227 for relapsed or refractory osteosarcoma after two prior lines of therapy.
HS-20093 (GSK'227) Receives FDA and EMA Designations for Osteosarcoma and SCLC
HS-20093/GSK'227, a B7-H3-targeted ADC, has been granted FDA Breakthrough Therapy Designation for relapsed or refractory osteosarcoma after two prior lines of therapy.
GSK's GSK5764227 Receives FDA Breakthrough Therapy Designation for Extensive-Stage Small Cell Lung Cancer
The FDA granted Breakthrough Therapy Designation to GSK5764227 for extensive-stage small cell lung cancer (ES-SCLC) post-platinum chemotherapy.
GSK Licenses Hansoh Pharma's B7-H3 ADC, HS-20093, for $185 Million Upfront
GSK has secured an exclusive license for HS-20093, a B7-H3-targeted antibody-drug conjugate (ADC) from Hansoh Pharma, excluding mainland China, Hong Kong, Macau, and Taiwan.